IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i1p93-112.html
   My bibliography  Save this article

Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique

Author

Listed:
  • Bonny Parkinson
  • Sallie-Anne Pearson
  • Rosalie Viney

Abstract

There were numerous drivers of the different conclusions regarding the cost-effectiveness of trastuzumab, many of which are due to judgements made by the authors when translating data from RCTs. Many of the potential drivers were not identified by the published systematic reviews of economic evaluations and perhaps more remain unidentified because of inconsistent and limited reporting. Copyright Springer-Verlag Berlin Heidelberg 2014

Suggested Citation

  • Bonny Parkinson & Sallie-Anne Pearson & Rosalie Viney, 2014. "Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 93-112, January.
    • Handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:93-112
    DOI: 10.1007/s10198-013-0459-2
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-013-0459-2
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-013-0459-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Nicola J. Cooper & Keith R. Abrams & Alex J. Sutton & David Turner & Paul C. Lambert, 2003. "A Bayesian approach to Markov modelling in cost‐effectiveness analyses: application to taxane use in advanced breast cancer," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 166(3), pages 389-405, October.
    2. Rob Anderson, 2010. "Systematic reviews of economic evaluations: utility or futility?," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 350-364, March.
    3. Michael F. Drummond, 1998. "Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals," Medical Decision Making, , vol. 18(2_suppl), pages 12-18, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Evgeni Dvortsin & Judith Gout-Zwart & Ernst-Lodewijk Marie Eijssen & Jan van Brussel & Maarten J Postma, 2016. "Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-12, January.
    2. Garattini, Livio & van de Vooren, Katelijne & Curto, Alessandro, 2015. "Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?," Health Policy, Elsevier, vol. 119(2), pages 212-216.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sanjib Saha & Ulf-G Gerdtham & Pia Johansson, 2010. "Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases," IJERPH, MDPI, vol. 7(8), pages 1-46, August.
    2. P. Watson & L. Preston & H. Squires & J. Chilcott & A. Brennan, 2014. "Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods," Applied Health Economics and Health Policy, Springer, vol. 12(3), pages 239-253, June.
    3. Lopert, Ruth & Ruiz, Francis & Chalkidou, Kalipso, 2013. "Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania," Health Policy, Elsevier, vol. 112(3), pages 202-208.
    4. Rajan Sharma & Yuanyuan Gu & Teresa Y. C. Ching & Vivienne Marnane & Bonny Parkinson, 2019. "Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique," Applied Health Economics and Health Policy, Springer, vol. 17(3), pages 331-357, June.
    5. Peter Bayer & Joel S. Brown & Johan Dubbeldam & Mark Broom, 2022. "A Markovian decision model of adaptive cancer treatment and quality of life," Post-Print hal-03767027, HAL.
    6. McClean, Sally & Gillespie, Jennifer & Garg, Lalit & Barton, Maria & Scotney, Bryan & Kullerton, Ken, 2014. "Using phase-type models to cost stroke patient care across health, social and community services," European Journal of Operational Research, Elsevier, vol. 236(1), pages 190-199.
    7. Chen Min & Mi Xue & Fei Haotian & Li Jialian & Zhang Lingli, 2021. "An overview of the characteristics and quality assessment criteria in systematic review of pharmacoeconomics," PLOS ONE, Public Library of Science, vol. 16(2), pages 1-13, February.
    8. Nora Döring & Susanne Mayer & Finn Rasmussen & Diana Sonntag, 2016. "Economic Evaluation of Obesity Prevention in Early Childhood: Methods, Limitations and Recommendations," IJERPH, MDPI, vol. 13(9), pages 1-11, September.
    9. Mandana Zanganeh & Peymane Adab & Bai Li & Emma Frew, 2019. "A Systematic Review of Methods, Study Quality, and Results of Economic Evaluation for Childhood and Adolescent Obesity Intervention," IJERPH, MDPI, vol. 16(3), pages 1-14, February.
    10. Vanessa Scarf & Christine Catling & Rosalie Viney & Caroline Homer, 2016. "Costing Alternative Birth Settings for Women at Low Risk of Complications: A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-17, February.
    11. Garattini, Livio & van de Vooren, Katelijne & Curto, Alessandro, 2015. "Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?," Health Policy, Elsevier, vol. 119(2), pages 212-216.
    12. Nadia Pillai & Mark Dusheiko & Bernard Burnand & Valérie Pittet, 2017. "A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-22, October.
    13. Tim Mathes & Maren Walgenbach & Sunya-Lee Antoine & Dawid Pieper & Michaela Eikermann, 2014. "Methods for Systematic Reviews of Health Economic Evaluations," Medical Decision Making, , vol. 34(7), pages 826-840, October.
    14. Hua Zhang & Mingdong Huo & Jianqian Chao & Pei Liu, 2016. "Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-9, August.
    15. Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva, 2017. "Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(4), pages 241-253, December.
    16. Katelijne Vooren & Alessandro Curto & Livio Garattini, 2015. "Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 341-345, May.
    17. Elisabet Jacobsen & Dwayne Boyers & Alison Avenell, 2020. "Challenges of Systematic Reviews of Economic Evaluations: A Review of Recent Reviews and an Obesity Case Study," PharmacoEconomics, Springer, vol. 38(3), pages 259-267, March.
    18. Kalle Hirvonen, 2020. "This is US: Geography of evidence in top health economics journals," Health Economics, John Wiley & Sons, Ltd., vol. 29(10), pages 1316-1323, October.
    19. Claudine Bommer & Judith Lupatsch & Nicole Bürki & Matthias Schwenkglenks, 2022. "Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(5), pages 807-821, July.
    20. A. E. Ades & A. J. Sutton, 2006. "Multiparameter evidence synthesis in epidemiology and medical decision‐making: current approaches," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 169(1), pages 5-35, January.

    More about this item

    Keywords

    Economics; Cost-utility analysis; Cost-effectiveness analysis; Breast neoplasms; Metastatic; Trastuzumab; I18; D61;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • D61 - Microeconomics - - Welfare Economics - - - Allocative Efficiency; Cost-Benefit Analysis

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:1:p:93-112. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.